<DOC>
	<DOCNO>NCT00931229</DOCNO>
	<brief_summary>This single-arm study . Key eligibility criterion include ( 1 ) newly diagnose , diffuse large B-cell follicular cell non-Hodgkin 's lymphoma ; ( 2 ) negative test hepatitis B surface antigen ( HBsAg ) positive antibody hepatitis B core antigen ( anti-HBc ) ; ( 3 ) adequate bone marrow , liver , kidney function . All eligible patient receive rituximab-CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) chemotherapy accord current treatment guideline . The primary endpoint study incidence hepatitis B virus ( HBV ) reactivation , define great 10-fold increase , compare previous nadir level , HBV DNA rituximab-CHOP chemotherapy within 1 year completion last course rituximab-CHOP chemotherapy . Patients HBV reactivation study period receive free entecavir treatment , one standard treatment chronic hepatitis B , 48 week . The secondary endpoint include incidence hepatitis flare , define great 3 fold increase serum alanine aminotransferase ( ALT ) level exceed 100 IU/L , efficacy safety rituximab-CHOP chemotherapy . In T1408 study enrol patient newly diagnose lymphoma HBsAg ( - ) anti-HBc ( + ) receive rituximab-CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) -based chemotherapy . Key finding study include ( 1 ) HBV reactivation , define great 10-fold increase HBV DNA compare previous nadir level , occur 10-20 % patient , depend sensitivity HBV DNA test ; ( 2 ) HBV-related death prompt anti-viral therapy upon HBV reactivation ; ( 3 ) patient HBV reactivation associate poor progression-free survival overall survival ; ( 4 ) serological breakthrough ( i.e. , re-appearance HBsAg ) important predictor HBV-related hepatitis flare . In amendment enroll patient clarify finding : ( 1 ) association HBV reactivation survival ; ( 2 ) diagnostic value quantitative HBsAg anti HBc test HBV reactivation ; ( 3 ) whether host factor ( DNA polymorphism ) may help predict HBV reactivation . A large patient cohort need identify ( 1 ) baseline feature may help predict HBV reactivation , ( 2 ) on-treatment feature may help timely anti-viral therapy .</brief_summary>
	<brief_title>Incidence Hepatitis B Reactivation Non-Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description>Treatment plan : A typical course rituximab-CHOP chemotherapy follow : rituximab 375 mg/m2 i.v. , day 1 , cyclophosphamide 750 mg/m2 i.v. , day 1 , doxorubicin 50 mg/m2 i.v. , day 1 , vincristine 1.4 mg/m2 ( maximal 2 mg ) i.v. , day 1 , prednisolone 40 mg/m2/day p.o. , day 1 day 5 . Typically treatment repeat every 3 week . If patient recover chemotherapy-induced toxicity schedule time next course treatment , modification chemotherapy dosage delay chemotherapy administration do accord local treatment standard record . The use component therapy granulocyte colony-stimulating factor discretion individual investigator . Auxiliary medication , anti-emetics , give accord local treatment guideline . Statistical consideration : 1 . Database Management Procedures Standard module description standard operation procedure data processing ensure quality validity data . 2 . Presentation Efficacy safety Endpoints 2.1 . The primary endpoint study incidence HBV reactivation , define great 10-fold increase , compare previous nadir level , HBV DNA , rituximab-CHOP chemotherapy within 1 year last course rituximab-CHOP chemotherapy . 2.2 . Secondary endpoint : Incidence hepatitis , define great 3 fold increase serum ALT level exceed 100 IU/L . Incidence severe hepatitis , define hepatitis flare increase ALT 10 fold ULN bilirubin 1.5 fold ULN . Association HBV reactivation serological breakthrough ( i.e. , re-appearance HBsAg ) follow-up Association HBV reactivation level anti-HBc antibody follow-up Association HBV reactivation HLA germline polymorphism ( HLA-DPA1 , HLA-DPB1 , HLA-DQA1 , HLA-DQB1 , HLA-DRB1 ) / IL28B genotype patient Progression-free survival overall survival patient receive rituximab-CHOP chemotherapy . 3 . Hypotheses Sample Size Determination It estimate Taiwan incidence 'resolved ' HBV infection general population 50 % . A recent survey HbsAg ( - ) blood donor indicate 7 % donor detectable HBV DNA serum . The incidence diffuse large B-cell non-Hodgkin 's lymphoma Taiwan 700-800 new patients/year ( Taiwan Cancer Registry , http : //crs.cph.ntu.edu.tw ) . We plan enroll 150 patient three year ( 50 new patient every year ) . 4 . General Statistical consideration 4.1 Randomization stratification This single-arm study . No randomization do . 4.2 Analysis population This study enroll NHL patient evidence 'resolved ' HBV infection . Eligible subject must negative serum HBV surface antigen ( HBsAg ) positive least one follow serum : anti-core antigen ( anti-HBc ) , anti-surface antigen ( anti-HBs ) , HBV DNA . Patients receive least 1 dose rituximab-CHOP chemotherapy enrol intent-to-treat population safety population . Patients complete least 1 course rituximab-CHOP chemotherapy enrol per-protocol analysis . The primary secondary endpoint describe Section 2.1 , 2.2 , 2.3 include per-protocol analysis . 4.3 Dropout Taking account 10 % dropout rate , need enter 62 patient per year trial may finish accrual patient within 3 year . 4.4 Baseline Before first course rituximab-CHOP chemotherapy , baseline characteristic patient measure . 4.5 Multicenter study This study conduct participate medical center Lymphoma Disease Committee ( 14 center total ) . Since rituximab-CHOP chemotherapy standard first-line treatment patient diffuse large B-cell NHL follicular cell NHL , center interaction treatment expect study . 4.6 Adjustment multiple test Adjustment multiple test need study . 4.7 Subgroup analysis Pre-specified subgroup analysis primary endpoint ( HBV reactivation rate ) do follow sub-groups : 1. baseline HBV DNA ( + ) vs. HBV DNA ( - ) ; 2. baseline alanine transaminase ( ALT ) normal vs. abnormal . 4.8 Patient Listings Individual patient listing also provide . 5 . Interim analysis data monitoring No interim analysis plan study . 6 . Final Analysis For final statistical analysis , section state specific statistical procedure describe item 6 section analysis every primary secondary efficacy safety endpoint .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Histologically proven diffuse large Bcell follicular Bcell nonHodgkin 's lymphoma , chemotherapy rituximabCHOP chemotherapy consider treatmentofchoice . 2 . Evidence 'resolved ' HBV infection . Eligible subject must negative serum HBV surface antigen ( HBsAg ) positive anticore antibody ( antiHBc ) . 3 . Age &gt; 18 year . 4 . Performance status ECOG score 02 . 5 . No previous chemotherapy radiotherapy , concurrent glucocorticoid use . 6 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 , platelet &gt; 100,000/mm3 peripheral blood . 7 . Total bilirubin ＜ 2.5 mg/dl . Alanine aminotransferase ( ALT ) ＜ 3 time UNL ( upper limit normal range ) . 8 . Serum creatinine ＜ 1.5 mg/dl . 9.10.Life expectancy 3 month . 11.Signed informed consent . 1 . Pregnant breastfeed woman . 2 . Patients history brain metastasis CNS involvement . 3 . Child 's class B C patient liver cirrhosis . 4 . Impaired cardiac function NYHA ( New York Heart Association ) classification Gr II . 5 . History liver diseases hepatitis C , D , autoimmune hepatitis , primary biliary cirrhosis , Wilsons ' disease . 6 . Other major systemic disease , active infection , significant cardiac disease , neurological deficit psychiatric disorder , investigator consider significant risk . 7 . Any concomitant cancer treatment . 8 . Known hypersensitivity study drug ( rituximab , cyclophosphamide , vincristine , doxorubicin , prednisolone ) . 9 . Known human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>hepatitis B reactivation</keyword>
</DOC>